|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 25, No 25 (September 1), 2007: pp. 3930-3935 © 2007 American Society of Clinical Oncology. DOI: 10.1200/JCO.2007.11.5022 Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy
From the Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti-Università Politecnica delle Marche, Ancona; Oncologia Medica, Ospedale Civico, Livorno - Università degli Studi di Pisa, Pisa; Oncologia Medica and Anatomia Patologica Casa di Cura Poliambulanza, Brescia; Oncologia Medica, AO San Salvatore, Pesaro; and Oncologia Medica, Ospedali Riuniti, Bergamo, Italy Address reprint requests to Stefano Cascinu, MD, Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy; e-mail: cascinu{at}yahoo.com Purpose: NF-kB expression has been shown to be responsible for resistance to antineoplastic agents and it also plays a part in the activation of the epidermal growth factor receptor downstream signaling pathway in colorectal tumors. The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan. Patients and Methods: We analyzed retrospectively the immunoreactivity for NF-kB in irinotecan-refractory patients receiving cetuximab and irinotecan.
Results: Seventy-six patients were analyzed. Cetuximab and irinotecan were administered as second-line chemotherapy in 19 patients and after Conclusion: The difference in median TTP, overall survival, and response rate seem to confirm that NF-kB may play a crucial role in predicting the efficacy of cetuximab and irinotecan in advanced colorectal tumors. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. Related Correspondence
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|